OTCMKTS:GBIM GlobeImmune (GBIM) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free GBIM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsShort InterestStock AnalysisChartFinancialsShort Interest Get GlobeImmune alerts: Email Address Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About GlobeImmune Stock (OTCMKTS:GBIM)GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.Read More Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here GBIM Stock News HeadlinesJuly 18, 2023 | investing.comBubang Co Ltd (014470)July 18, 2023 | investing.comNihon Knowledge Co Ltd (5252)March 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.April 21, 2023 | nasdaq.comNuvista Energy Breaks Below 200-Day Moving Average - Notable for NVAJanuary 9, 2023 | sg.finance.yahoo.comGlobeImmune, Inc. (GBIM) stock historical prices & data – Yahoo FinanceSeptember 15, 2022 | reuters.comGBIM.PK - GlobeImmune Inc | Stock Price & Latest News | ReutersSee More Headlines Receive GBIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlobeImmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/12/2016Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:GBIM Previous SymbolNASDAQ:GBIM CUSIPN/A CIK1245104 Webwww.globeimmune.com Phone(720) 667-2300Fax303-625-2710Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-193.85 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. C. Jeffrey Dekker CPA (Age 59)President, Vice President of Finance, Treasurer & Secretary Comp: $200.05kDr. Richard C. DukeScientific Founder & Member of Scientific Advisory BoardDr. Donald BellgrauScientific Founder & Chairman of The Scientific Advisory BoardKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors GBIM Stock Analysis - Frequently Asked Questions How were GlobeImmune's earnings last quarter? GlobeImmune, Inc. (OTCMKTS:GBIM) released its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter. What other stocks do shareholders of GlobeImmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlobeImmune investors own include OHR Pharmaceutical (OHRP), Novavax (NVAX), Premier Gold Mines (PG), Algonquin Power & Utilities (AQN), Nordic American Tankers (NAT), (BAA) (BAA), Petróleo Brasileiro S.A. - Petrobras (PBR), Pengrowth Energy (PGH), Absolute Software Co. (ABT.TO) (ABT) and Alacer Gold (ASR). How do I buy shares of GlobeImmune? Shares of GBIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GBIM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlobeImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.